Aktuellt
SENASTE
Q1 sales were SEK 27m (+5% vs SEB 25.8) with all sales now coming from the orthobiologics business. Like for like and at constant exchange rates, this corresponds to y/y growth of 207%. With a strong gross margin and opex also being somewhat better, Q1 EBIT was SEK -12m (SEBe: SEK -17m). Strong top line now also combined with strong cost control although the company says that at the start of year opex was somewhat lower than the expected level going forward.
LÄS MER
